Isn't his point that if the FDA concludes that tailoring their sameness criteria to the submissions of one company is going to lead to that company having a monopoly (as that company will patent their techniques), they may look for an alternative if possible? I suppose that depends if the FDA mandate includes fostering greater competition, which seems to me clearly a purpose of Hatch-Waxman.
Market Data 
Markets 
AI
